Cassie’s practice primarily involves advising health care clients on transactional and regulatory matters, including mergers and acquisitions, regulatory compliance, and general contracting.
Throughout her career, Cassie has worked with providers, payors, and individual patients, so she understands the unique challenges facing clients in the ever-changing health care landscape.
Prior to joining Mintz, Cassie worked as in-house counsel at a national senior living company. There she advised the business on matters related to state and federal health care regulations, physician arrangements, reimbursement, fraud and abuse, and HIPAA/privacy. She also oversaw all contracting matters for the company’s skilled nursing division.
Cassie’s in-house experience informs current her practice, enabling her to anticipate and relate to clients’ legal and business needs.
During her time at Suffolk University Law School, Cassie had the privilege of representing indigent clients before the Social Security Administration and Suffolk Probate Court as a student attorney with the school’s Health Law Clinic. She also served as Editor-in-Chief of Suffolk’s Journal of Health & Biomedical Law.
Education
- Suffolk University Law School (JD, summa cum laude)
- Boston College (BA, cum laude)
Involvement
- Member, American Health Lawyers Association
- Member, Boston Bar Association
Recent Insights
Viewpoints
Viewpoints
Part 2 Proposed Rule Brings Clarity and Reduces Regulatory Burdens for Substance Use Disorder Providers, but Challenges Remain
September 3, 2019 | Blog | By Dianne Bourque, Cassandra Paolillo
On August 22, the Substance Abuse and Mental Health Services Administration (“SAMHSA”) announced a new proposed rule (the “Proposed Rule”) amending 42 CFR part 2 (“Part 2”), which is aimed at protecting patient records created by federally funded programs for the treatment of substance use disorder (“SUD”). The Proposed Rule is aimed at alleviating these concerns within the constraints of the underlying statute, while also addressing the increasingly urgent need to streamline SUD services in light of the opioid epidemic. Here we’ll discuss some of the major changes under the Proposed Rule while highlighting the challenges that remain.
Recent Executive Order Makes the Road to Increased Healthcare Transparency Unclear
July 2, 2019 | Blog | By Cassandra Paolillo
Last week, President Trump signed an “Executive Order on Improving Price and Quality Transparency in American Healthcare to Put Patients First.” The order, which “seeks to enhance the ability of patients to choose the healthcare that is best for them,” includes a number of provisions requiring the Departments of Health and Human Services, Labor, Treasury and others to pass regulations to increase transparency for patients. The following is a summary of the executive order and a brief overview of what providers and others in the healthcare industry can anticipate going forward.
Mintz and ML Strategies Host the 4th Annual Pharmacy & Pharmaceutical Industry Summit
May 10, 2019 | Blog | By Cassandra Paolillo
Last week, Mintz and ML Strategies welcomed stakeholders and thought leaders from across the pharmacy and pharmaceutical industry to the Boston Office for the 4th Annual Pharmacy & Pharmaceutical Industry Summit.
Judge Dismisses FCA Claims Against Compounding Pharmacy and Private Equity Firm Owner but Allows the Government to Amend
March 13, 2019 | Blog | By Karen Lovitch, Cassandra Paolillo
Last week, a U.S. district court judge in the Southern District of Florida upheld a magistrate judge’s decision to dismiss False Claims Act (FCA) allegations against a compounding pharmacy, its private equity firm owner, and two individuals. DOJ filed its complaint in intervention last February against the pharmacy, Patient Care America (PCA); its private equity backer, Riordan Lewis & Haden, Inc.; and two individual executives. The government alleged that the parties engaged in an illegal kickback scheme that resulted in the submission of false claims to TRICARE for expensive compounded drugs. This case is reportedly the first in which the federal government intervened against a private equity firm owner.
Independent Laboratory Settles Medical Necessity Allegations
February 20, 2019 | Blog | By Karen Lovitch, Cassandra Paolillo
The Department of Justice (DOJ) recently announced a $1.99 million False Claims Act (FCA) settlement with GenomeDx Biosciences Corp. (“GenomeDx”), a laboratory headquartered in Vancouver, British Columbia with operations in San Diego. The matter arose as the result of a qui tam case brought by two former employees in September 2017.
OIG Advisory Opinion Allows Routine Waiver of Federal Cost-Sharing Obligations
January 18, 2019 | Blog | By Karen Lovitch, Cassandra Paolillo
In an Advisory Opinion posted earlier this week, the OIG gave the green light to a charitable pediatric clinic’s routine waiver of patient cost-sharing amounts on the basis. The OIG’s analysis hinged on several factors that, taken together, led the OIG to refrain from exercising its enforcement discretion.
As 2019 Approaches, Private Equity Investment in Health Care Shows No Signs of Slowing Down
December 26, 2018 | Blog | By Cassandra Paolillo
As the year draws to a close, it’s clear that 2018 was another record year for private equity investment in health care. In its report on the top health industry issues of 2019, PWC’s Healthcare Research Institute recently highlighted the continued prevalence of private equity in health care transactions, and predicted even more private equity investment in the coming year. Below is an overview of the current and expected trends, as well as a few key considerations for private equity deals in the health care space.
HPC Weighs in on Impact of Question 1
November 1, 2018 | Advisory | By Elissa Flynn-Poppey, Cassandra Paolillo, Stephen Weiner
This article discusses a Massachusetts Health Policy Commission report on the impact of Questions 1, the proposed Nurse Staffing Ratio Mandate.
Massachusetts HPC Health Care Cost Trends Hearing: Key Takeaways
October 24, 2018 | Blog | By Daria Niewenhous, Caitlin Beresin, Rachel Irving Pitts, Cassandra Paolillo
The Massachusetts Health Policy Commission (“HPC”) held its annual Health Care Cost Trends Hearing on October 16-17, 2018. The hearing covered a wide range of topics affecting the health care industry here in the Commonwealth and across the country. Here are some key takeaways and a legislative outlook.
Final Opioid Legislation Expands Treatment Options for Medicaid Beneficiaries with Substance Use Disorder
October 5, 2018 | Blog | By Cassandra Paolillo
The final bipartisan opioid package, which passed in the Senate this week and is expected to be signed into law, includes a significant revision from the original House bill that could lead to an increase in treatment options for Medicaid beneficiaries suffering from substance use disorder (“SUD”). The final version of the “SUPPORT for Patients and Communities Act” will provide state Medicaid programs with the option to cover SUD treatment in certain Institutions for Mental Diseases (“IMD”) for Medicaid beneficiaries between the ages of 21 and 64.